share_log

BeiGene Will Not Go Forward With Licensing Pact For Leap Therapeutics' Lead Cancer Candidate

BeiGene Will Not Go Forward With Licensing Pact For Leap Therapeutics' Lead Cancer Candidate

百济神州不会继续签订 Leap Therapeutics 主要癌症候选药物的许可协议
Benzinga ·  2023/03/17 10:30
  • Leap Therapeutics Inc (NASDAQ:LPTX) announced BeiGene Ltd's (NASDAQ:BGNE) option under the Exclusive Option, and License Agreement granting rights in certain Asian territories to DKN-01 has expired.
  • The companies announced an option agreement in January 2020 for DKN-01 in Asia (excluding Japan), Australia, and New Zealand.
  • Leap and BeiGene will continue collaborating on Part C of the DisTinGuish trial, a randomized controlled trial of DKN-01 combined with BeiGene's tislelizumab and chemotherapy in first-line gastric cancer patients, as a clinical collaboration with BeiGene supplying tislelizumab.
  • Enrollment in the 160-patient study is expected to be completed in late 2023.
  • Related: Leap Therapeutics Says DKN-01 Combo Regime Show Compelling Efficacy In Gastric Cancer Patients.
  • "With global rights to DKN-01 and a cash runway that was enhanced into mid-2025 by our recent acquisition of Flame Biosciences, we will look to identify a new strategic partner as we generate new clinical data from our ongoing studies in first-line gastric cancer patients, second-line colorectal cancer patients, and an investigator-sponsored study in endometrial cancer patients," said Douglas E. Onsi, President & CEO of Leap.
  • Earlier this month, Leap Therapeutics agreed to acquire Flame Biosciences Inc, a privately-held biotechnology company, in an all-stock transaction.
  • Price Action: LPTX shares are down 13.2% at $0.38 on the last check Friday.
  • Leap Therape （纳斯达克股票代码：LPTX）宣布 百济神州有限公司 （纳斯达克股票代码：BGNE）独家期权下的期权以及授予 DKN-01 在某些亚洲地区的权利的许可协议已到期。
  • 两家公司于 2020 年 1 月宣布了亚洲（不包括日本）、澳大利亚和新西兰的 DKN-01 期权协议。
  • Leap 和 BeiGene将继续合作进行区分试验的C部分，这是一项与 DKN-01 联合百济神州替雷利珠单抗和一线胃癌患者化疗的随机对照试验，是与提供替雷利珠单抗的百济神州开展的临床合作。
  • 这项160名患者的研究的注册预计将于2023年底完成。
  • 相关： Leap Therapeutics 表示，DKN-01 组合疗法在胃癌患者中显示出令人信服。
  • Leap总裁兼首席执行官道格拉斯·昂西表示：“凭借 DKN-01 的全球版权，以及我们最近对Flame Biosciences的收购，到2025年中期，随着我们正在进行的对一线胃癌患者、二线结直肠癌患者的研究以及研究人员赞助的子宫内膜癌患者研究得出新的临床数据，我们将寻求寻找新的战略合作伙伴。”
  • 本月初，Leap Therapeutics同意收购 Flame 生物科学公司，一家私营生物技术公司，正在进行全股交易。
  • 价格走势： 在周五的最后一次支票中，LPTX股价下跌了13.2％，至0.38美元。
声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发